Targeting ETV1 in Gastrointestinal Stromal Tumors: Tripping the Circuit Breaker in GIST?

Anette Duensing1,2

Summary: Activating mutations in the KIT or PDGFRA receptor tyrosine kinase genes are the key oncogenic drivers in the majority of gastrointestinal stromal tumors (GIST), but novel results now show that aberrant kinase signaling is potentiated by a positive feedback circuit that involves the ETS transcription factor ETV1. Targeting ETV1 can disrupt this circuit and represents a promising new therapeutic approach for the treatment of GISTs.

Cancer Discov; 5(3); 231–3. ©2015 AACR.

See related article by Ran and colleagues, p. 304 [5].

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract and one of the most common subtypes of sarcomas. Because of their unique molecular properties, GISTs spearheaded the use of targeted therapies in solid tumors, a concept that eventually led to a paradigm shift in oncologic therapy. GISTs were the first solid tumor entity that could successfully be treated with small-molecule inhibitors, specifically tyrosine kinase inhibitors such as imatinib mesylate (Gleevec; ref. 1). This notion came shortly after the discovery that an oncogenic mutation in the KIT (75%–85%) or PDGFRA (platelet-derived growth factor receptor alpha; 5%–7%) gene is the tumor-initiating event in the vast majority of GISTs and leads to constitutive activation of the encoded receptor tyrosine kinase (2, 3). Major responses are seen after first-line treatment with the KIT/PDGFRA inhibitor imatinib, and approximately 85% of patients with metastatic and/or inoperable GIST benefit from this therapy. However, complete tumor remissions are rare, and about 50% of patients experience disease recurrence within 2 years of treatment. There are several reasons for this, including the emergence of secondary mutations in KIT/PDGFRA that confer drug resistance, entry into a state of cellular quiescence, and the potential existence of GIST stem/progenitor cells that express low levels of KIT and are intrinsically imatinib resistant. Given these reasons, it is unlikely that GISTs can be cured with imatinib alone, and additional therapeutic approaches are urgently needed.

GISTs are thought to arise from a specialized cell type in the bowel wall, the interstitial cells of Cajal (ICC), or a common progenitor. These cells are present throughout the entire digestive tract, where they serve as pacemaker cells to coordinate peristalsis. Interestingly, there are several subsets of ICs that are located in distinct microscopical locations within the gut, and only certain types seem to give rise to GIST. In an earlier study, Chi and colleagues (4) discovered that the ETV1 transcription factor is a master regulator not only of the ICC population giving rise to GIST, but also of an ICC-GIST-specific transcriptional network. ETV1 is highly expressed in GISTs (but not in other sarcomas) and is required for the growth and proliferation of GIST cells.

A new study by the same group (5), published in this issue of Cancer Discovery, adds an important new spin to their previous observations. The latest data not only provide in vivo validation of their experimental findings; more importantly, ETV1 is identified as part of a positive feedback circuit involving KIT and MAPK signaling and hence firmly established as a key therapeutic target in GIST.

Building on their original observation that the loss of ETV1 in a mouse model leads to loss of the specific ICC subtypes that are known to give rise to GIST, Ran and colleagues now ask whether ETV1 is crucial for the development of these tumors. Indeed, when Etv1−/− mice are crossed with KitV558Δ/+ mice (which are known to develop GIST-like tumors in the cecum as well as ICC hyperplasia throughout the gastrointestinal tract; ref. 6), no tumors are detected, indicating that ETV1 is required for the development of GIST. Interestingly, however, Etv1−/−;KitV558Δ/+ mice can develop ICC hyperplasia. This finding suggests that constitutive activation of KIT on its own does induce a proliferative stimulus in ICCs—which is likely executed via other transcription factors—but that ETV1 is necessary for tumor formation. Notably, the importance of ETV1 for GIST maintenance is confirmed in a conditional knockout mouse model (Etv1flh/flh;KitV558Δ/+; Rosa26CreERT2). Temporary reduction of ETV1 levels decreases proliferation of the GIST-like tumors in the cecum of these animals (as well as of the ICC hyperplasia), while also inducing tumor fibrosis as a correlate of tumor regression. These results confirm earlier observations that reduction of ETV1 levels (by shRNA) in GIST cell lines and xenografts decreases cellular proliferation (4).

One main finding of the current study is that ETV1 and KIT form a positive feedback circuit to regulate the expression of target genes in GIST. The first clue to this notion came from the authors’ previous experiments, which showed that inhibition of KIT led to a substantial downregulation of ETV1 protein expression levels. When now examining the
ETV1-regulated transcriptome in cecal tumors of \(Etv1^{lox/lox}, Kit^{flox/flox};Rosata26^{CreERT2/CaERT2}\) mice using Gene Set Enrichment Analysis (GSEA), the authors discover that the most enriched gene set among those downregulated after ETV1 ablation is the set of genes most downregulated by imatinib treatment in the GIST-like tumors of \(Kit^{SSK67/}\) mice. The same results are obtained when looking at shRNA- or CRISPR/Cas9-mediated knockdown of ETV1 in human GIST cell line models, indicating that ETV1 and KIT regulate a common core transcriptional program.

Ran and colleagues next address the question whether ETV1—an ETS family transcription factor—could directly regulate KIT gene expression. Indeed, ablation of \(Etv1\) in \(Etv1^{lox/lox}, Kit^{SSK67/}^{lox/lox}, \text{Rosa}26^{CreERT2/CaERT2}\) mice leads not only to the downregulation of known ETV1 target genes (such as \(Dnajb9, \text{Gpr}20, \text{and Edn}3\)) but also to downregulation of KIT mRNA expression. This is accompanied by reduced KIT protein expression in the cecal GIST-like tumors and ICC hyperplasia of the animals. Together, these results indicate that KIT may be a direct transcriptional target of ETV1. The fact that overexpression of ETV1 leads to upregulation of KIT mRNA expression and that chromatin immunoprecipitation-sequencing (ChIP-seq) analyses show multiple ETV1 binding sites in the KIT enhancer substantiates this hypothesis. Ultimately, ChIP-qPCR experiments establish direct binding of ETV1 to these sites, and hence show that ETV1 can directly regulate KIT expression levels. ETV1 therefore cooperates with mutant KIT by forming a positive feedback loop to promote GIST pathogenesis (Fig. 1A).

Establishing a positive feedback circuit involving KIT and ETV1 further underscores the role of ETV1 as a potential therapeutic target in addition to KIT inhibition in GIST. But how to avoid the activity of a transcription factor? Although having long been desirable targets for cancer treatment, transcription factors are inherently difficult to tackle using common therapeutic strategies. The reason for this mainly lies in their large surface area for protein–DNA and protein–protein interactions in addition to their nuclear localization (7). Here, luckily, the authors had already found a clue from their previous work (4). ETV1 stability is regulated by MAPK signaling, which is one important signaling axis downstream of KIT. Thus, chemical inhibition not only of KIT but also of MEK leads to a rapid reduction in ETV1 levels.

In their current study, Ran and colleagues take these findings to the next level and investigate the efficacy as well as mechanism of action of MEK162, a MEK inhibitor that is already in late-stage clinical trials. They confirm that MEK162 (as well as imatinib) treatment destabilizes ETV1, leads to reduced binding of ETV1 at the KIT enhancer and, most importantly, reduces cell viability \textit{in vitro}. Notably, combining imatinib and MEK162 has a synergistic effect on both ETV1 destabilization and cell viability, making it possible to reduce the doses of both agents (Fig. 1B).

Ran and colleagues finally go on to show that a combined treatment with imatinib and MEK162 leads to nearly complete and durable responses in two GIST xenograft models, whereas single treatment with imatinib leads only to disease stabilization (a notion that has been reported in several other studies). Similar results are obtained when treating \(Kit^{SSK67/}\) transgenic mice. When investigating the mechanism of action of the treatment, the authors confirm a dramatic loss of ETV1 expression, especially in the animals treated with the drug combination.

What is next? A clinical trial (phase Ib/II) testing the concept of ETV1 inhibition via combined imatinib/MEK162 treatment has been designed (NCT01991379) and has already started patient accrual. In addition, this study has shown once more how important it is to identify additional therapeutic options for patients with GIST that make use of these tumors’ specific molecular makeup aside from KIT/\(PDGFRA\) mutations. Especially targeting the transcriptional machinery—either globally or with the aim of reducing the expression levels of specific genes (such as KIT and ETV1)—has recently emerged as an important new angle for the treatment of GIST and other oncogene-driven malignancies (8–10). For example, inhibitors of the 26S proteasome, such as bortezomib (Velcade), have been shown to inhibit ongoing gene transcription in GIST, leading to a dramatic loss of KIT protein expression and subsequent apoptosis (8). The \(SP1\) inhibitor mithramycin A, a “classical” transcriptional inhibitor, has recently gained attention again for being the top hit in a 50,000 compound screen against the \(EWS–FLI1\) fusion oncogene in Ewing family sarcoma (9). It was also identified in a smaller library screen as being effective for GISTs, with its main mechanism of action lying in the reduction of KIT.
expression levels (10). Specifically in GIST, targeting gene transcription and its regulators allows the bypass of secondary KIT/PDGFRα mutations that emerge during tyrosine kinase inhibitor treatment, thus paving the way to a more complete eradication of tumor cells.

Taken together, the work presented by Ran and colleagues proves once more that KIT/PDGFRα-associated regulatory networks are the Achilles heel of GIST, and that a better understanding of these intracellular signaling circuits holds the promise of more complete and long-lasting remissions for patients with GIST.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Disclaimer
The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations, or conclusions in this work.

Acknowledgments
The author thanks Stefan Duensing for critically reading this article and for helpful discussions.

Grant Support
The Duensing laboratory is supported by grants from the GIST Cancer Research Fund, The Life Raft Group (AD-UPCC-010115), and the GIST-Gruppe Schweiz. The author is supported by the University of Pittsburgh Cancer Institute and, in part, by a grant from the Pennsylvania Department of Health.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Disclaimer
The Pennsylvania Department of Health specifically disclaims responsibility for any analyses, interpretations, or conclusions in this work.

Acknowledgments
The author thanks Stefan Duensing for critically reading this article and for helpful discussions.

Grant Support
The Duensing laboratory is supported by grants from the GIST Cancer Research Fund, The Life Raft Group (AD-UPCC-010115), and the GIST-Gruppe Schweiz. The author is supported by the University of Pittsburgh Cancer Institute and, in part, by a grant from the Pennsylvania Department of Health.

Published online March 6, 2015.
Targeting ETV1 in Gastrointestinal Stromal Tumors: Tripping the Circuit Breaker in GIST?

Anette Duensing


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://cancerdiscovery.aacrjournals.org/content/5/3/231">http://cancerdiscovery.aacrjournals.org/content/5/3/231</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cited articles</td>
<td>This article cites 10 articles, 6 of which you can access for free at: <a href="http://cancerdiscovery.aacrjournals.org/content/5/3/231.full#ref-list-1">http://cancerdiscovery.aacrjournals.org/content/5/3/231.full#ref-list-1</a></td>
</tr>
<tr>
<td>E-mail alerts</td>
<td>Sign up to receive free email-alerts related to this article or journal.</td>
</tr>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>